Biosimilars | Current Treatment | Nephrology | US/EU | 2016
The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to their chronic kidney disease (CKD) patients for a number of years, but no biosimilar ESAs are yet available to U.S. nephrologists. As new biosimilars near the market, including epoetin alpha biosimilars in the United States, it is important to understand how and why ESA biosimilar uptake is so varied. We surveyed French, German, and U.S. nephrologists about their familiarity with, use of, and attitude toward current biosimilars; the drivers and barriers to biosimilars’ uptake; and these physicians’ expectations for novel biosimilars.
Related Market Assessment Reports
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
